MPM BioImpact LLC
Sector Allocation
- Healthcare100.0%$1.6B
AUM History
13fpro.ai/research/fund/mpm-bioimpact-llc-1687078
Conviction and streaks
Concentrating · top 10 = 55.3%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q2 2026
CGEM
$177.2MAKTS
$155.9MLQDA
$110.5MRVMD
$92.2MCORT
$67.0MEWTX
$65.9MTVTX
$63.8MDBVT
$60.1MTRVI
$57.3MALMS
$56.8MQURE
$56.5MRARE
$47.4MRLAY
$45.2MABVX
$44.8MDYN
$42.7MDNTH
$40.9MBIOA
$40.9MURGN
$34.3MMLTX
$31.3MPVLA
$31.2M
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/mpm-bioimpact-llc-1687078
MPM BioImpact LLC 13F holdings — Q2 2026
$1.6B portfolio (+26.6% QoQ) · 37 holdings · Q2 2026 13F · top 10 are 55% of the stock portfolio
$177.2M
10.8% of stocks
+27%This quarter-28.5%Since filed10+ qtrsHeld$155.9M
9.5% of stocks
No changeThis quarter-36.9%Since filed2 qtrsHeld$110.5M
6.7% of stocks
-1%This quarter-41.2%Since filed4 qtrsHeld$92.2M
5.6% of stocks
-3%This quarter-9.7%Since filed10+ qtrsHeld$67.0M
4.1% of stocks
-22%This quarter-23.9%Since filed2 qtrsHeld$65.9M
4.0% of stocks
-2%This quarter-11.3%Since filed10+ qtrsHeld$63.8M
3.9% of stocks
-0.9%This quarter-19.6%Since filed2 qtrsHeld$60.1M
3.7% of stocks
-30%This quarter-28.8%Since filed5 qtrsHeld$57.3M
3.5% of stocks
-7%This quarter-32.2%Since filed10+ qtrsHeld$56.8M
3.5% of stocks
-15%This quarter-74.3%Since filed3 qtrsHeld
All holdings — MPM BioImpact LLC (Q2 2026)
37 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | uniQure N.V. | Healthcare | $56.5M | 3.4% | 1.23M | -10% | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | Ultragenyx Pharmaceutical Inc. | Healthcare | $47.4M | 2.9% | 1.42M | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | Relay Therapeutics, Inc. | Healthcare | $45.2M | 2.8% | 2.42M | +2% | 10+ qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | Abivax S.A. | Healthcare | $44.8M | 2.7% | 336K | +214% | 3 qtrsAdded 3 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | Dyne Therapeutics, Inc. | Healthcare | $42.7M | 2.6% | 1.92M | +36% | 5 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | Dianthus Therapeutics, Inc. /DE/ | Healthcare | $40.9M | 2.5% | 420K | -0.9% | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | BioAge Labs, Inc. | Healthcare | $40.9M | 2.5% | 1.67M | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | UroGen Pharma Ltd. | Healthcare | $34.3M | 2.1% | 933K | -1% | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | MoonLake Immunotherapeutics | Healthcare | $31.3M | 1.9% | 1.61M | -11% | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 20 | PALVELLA THERAPEUTICS, INC. | Healthcare | $31.2M | 1.9% | 204K | -1% | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 21 | Taysha Gene Therapies, Inc. | Healthcare | $30.6M | 1.9% | 4.50M | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 22 | Syndax Pharmaceuticals Inc | Healthcare | $29.2M | 1.8% | 1.33M | -0.5% | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 23 | Monte Rosa Therapeutics, Inc. | Healthcare | $28.1M | 1.7% | 1.16M | -1% | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 24 | Zura Bio Ltd | Healthcare | $26.4M | 1.6% | 4.47M | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 25 | Natera, Inc. | Healthcare | $25.1M | 1.5% | 93K | -0.5% | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 26 | $STOK | Stoke Therapeutics, Inc. | Healthcare | $23.7M | 1.4% | 723K | -6% | |||
| 27 | $ANL | Adlai Nortye Group Ltd. | Healthcare | $22.3M | 1.4% | 1.94M | New | |||
| 28 | $BLTE | BELITE BIO, INC | Healthcare | $21.1M | 1.3% | 137K | +56% | |||
| 29 | $FBRX | Forte Biosciences, Inc. | Healthcare | $21.0M | 1.3% | 987K | -1% | |||
| 30 | $ORIC | Oric Pharmaceuticals, Inc. | Healthcare | $20.4M | 1.2% | 1.88M | +4% | |||
| 31 | $TARS | Tarsus Pharmaceuticals, Inc. | Healthcare | $20.3M | 1.2% | 322K | -2% | |||
| 32 | $ANNX | Annexon, Inc. | Healthcare | $20.2M | 1.2% | 3.54M | New | |||
| 33 | $DRUG | BRIGHT MINDS BIOSCIENCES INC. | Healthcare | $14.2M | 0.9% | 202K | -5% | |||
| 34 | $TRDA | Entrada Therapeutics, Inc. | Healthcare | $9.2M | 0.6% | 1.25M | New | |||
| 35 | $ACRS | Aclaris Therapeutics, Inc. | Healthcare | $5.5M | 0.3% | 1.04M | +166% | |||
| 36 | $CNTX | Context Therapeutics Inc. | Healthcare | $720K | 0.0% | 1.30M | -88% | |||
| 37 | $HOWL | Werewolf Therapeutics, Inc. | Healthcare | $29K | 0.0% | 80K | -93% |
What changed in Q2 2026
Against the previous quarter's 13F: 7 new, 7 added to, 22 trimmed, 11 sold out. Share-count changes; largest moves by dollar size first.
New positions (7)
first bought this quarter
first bought this quarter
$TSHATaysha Gene Therapies, Inc.$30.6M
first bought this quarter
$ZURAZura Bio Ltd$26.4M
first bought this quarter
$ANLAdlai Nortye Group Ltd.$22.3M
first bought this quarter
$ANNXAnnexon, Inc.$20.2M
first bought this quarter
+1 more in the Excel export
Added to (7)
now $177.2M · held 10+ qtrs
now $44.8M · held 3 qtrs, 3 adds in a row
now $42.7M · held 5 qtrs
$BLTEBELITE BIO, INC+56%
now $21.1M · held 3 qtrs
$ACRSAclaris Therapeutics, Inc.+166%
now $5.5M · held 2 qtrs, 2 adds in a row
now $45.2M · held 10+ qtrs, 2 adds in a row
+1 more in the Excel export
Trimmed (22)
now $60.1M · held 5 qtrs
now $67.0M · held 2 qtrs
now $56.8M · held 3 qtrs
now $56.5M · held 3 qtrs
$CNTXContext Therapeutics Inc.-88%
now $720K · held 7 qtrs
now $57.3M · held 10+ qtrs
+16 more in the Excel export
Sold out (11)
$AGIOAGIOS PHARMACEUTICALS, INC.was $44.2M
held 2 qtrs
$XENEXenon Pharmaceuticals Inc.was $34.2M
held 7 qtrs
$EVMNEvommune, Inc.was $33.5M
held 2 qtrs
$CYTKCYTOKINETICS INCwas $33.0M
held 1 qtr
$CRVSCorvus Pharmaceuticals, Inc.was $24.5M
held 2 qtrs
$CLYMClimb Bio, Inc.was $17.8M
+5 more in the Excel export
Holdings by quarter
Every 13F MPM BioImpact LLC has filed, 26 earlier quarters. Pick one to see what it held then.
Is it too late to follow MPM BioImpact?
Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of MPM BioImpact's top 20 holdings: 46/100 (our AI quality score, weighted by position size; 8 of the 20 are scored)
Top 10 since filing
-30.5%
Value-weighted move of the 10 largest stock positions
Turnover
20%
Last quarter; 78% over the last 4
Top 10 weight
55%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
51%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
MPM BioImpact LLC disclosed 37 positions worth $1.6B in its Form 13F-HR for Q2 2026, led by $CGEM (Cullinan Therapeutics, Inc.) at 10.8% of the equity portfolio, followed by $AKTS and $LQDA. During the quarter the fund opened 7 new positions and exited 11 — including a new stake in $RARE and a full exit from $AGIO. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from MPM BioImpact LLC’s Form 13F-HR filing with the SEC under CIK 1687078.
Funds like this
managers whose biggest positions overlap MPM BioImpact'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: MPM BioImpact LLC
13F Pro is an AI hedge fund tracker and stock research platform. For MPM BioImpact LLC (SEC CIK: 1687078), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in MPM BioImpact LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.